These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27125054)

  • 1. Performance Improvement in 503A Compounding Pharmacies: A PLAN FOR ASSESSMENT, IMPLEMENTATION, AND SUSTAINED SUCCESS.
    Pritchett J; Mixon W; O'Connell K
    Int J Pharm Compd; 2016; 20(1):29-36. PubMed ID: 27125054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2016; 20(6):481-484. PubMed ID: 28339387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality planning, part 1: a holistic and practical approach.
    Odegard RD
    Int J Pharm Compd; 2013; 17(5):393-9. PubMed ID: 24459786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies.
    Pritchett J; McCrory G; Kraemer C; Jensen B; Allen LV
    Int J Pharm Compd; 2018; 22(1):7-16. PubMed ID: 29385381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytic Methods Used in Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2017; 21(1):31-37. PubMed ID: 28346196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2013 State Compounding Legislation Tracker.
    Miller DG
    Int J Pharm Compd; 2013; 17(5):375-8. PubMed ID: 24459782
    [No Abstract]   [Full Text] [Related]  

  • 9. Brazilian National System for the Monitoring and Improvement of Compounding Practices: program outcomes.
    de Souza HG; Favaro A; Andrade AL; Gomes LY; Garcez Mdo C
    Int J Pharm Compd; 2012; 16(2):98-102. PubMed ID: 23050320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
    Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
    [No Abstract]   [Full Text] [Related]  

  • 12. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance.
    Greeson NM; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "Lists": What Do They Mean?
    Voliva J
    Int J Pharm Compd; 2016; 20(6):477-479. PubMed ID: 28339386
    [No Abstract]   [Full Text] [Related]  

  • 15. The art, science, and practice of pharmacy compounding.
    McDonough RP; Allen LV; Wettergreen S
    J Am Pharm Assoc (2003); 2013; 53(1):8-12. PubMed ID: 23636149
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA, states discuss pharmacy compounding regulatory framework.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
    Minghetti P; Pantano D; Gennari CG; Casiraghi A
    Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial Identification in Pharmaceutical Compounding.
    Hyde T; Anstead J; Schade L; Zellner J
    Int J Pharm Compd; 2016; 20(1):13-8. PubMed ID: 27125052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.